Second Circuit Revives Whistleblower Kickback Claims Alleging “Sham” Speaker Program
- January 10, 2025
Novartis Pharmaceuticals Corporation must face allegations it offered unlawful remuneration to physicians through a “sham” speaker program aimed at inducing their prescription of the company’s multiple sclerosis (MS) drug Gilenya, the Second Circuit held December 27, 2024 in partially reviving a False Claims Act (FCA) qui tam action.
ARTICLE TAGS
You must be logged in to access this content.